tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ovid Therapeutics reports Q2 EPS (6c), consensus (15c)
PremiumThe FlyOvid Therapeutics reports Q2 EPS (6c), consensus (15c)
3d ago
Ovid Therapeutics sees cash runway into 2H26
Premium
The Fly
Ovid Therapeutics sees cash runway into 2H26
3d ago
Ovid Therapeutics initiated with a Buy at Lucid Capital
Premium
The Fly
Ovid Therapeutics initiated with a Buy at Lucid Capital
3d ago
Ovid enters agreement with Immedica for sale of future ganaxolone royalties
PremiumThe FlyOvid enters agreement with Immedica for sale of future ganaxolone royalties
2M ago
Ovid Therapeutics: Promising Buy Opportunity with OV329 Advancements in Drug-Resistant Epilepsy
Premium
Ratings
Ovid Therapeutics: Promising Buy Opportunity with OV329 Advancements in Drug-Resistant Epilepsy
2M ago
Positive Outlook for Ovid Therapeutics: Buy Rating Supported by Promising OV329 Drug and Strategic Pipeline Development
Premium
Ratings
Positive Outlook for Ovid Therapeutics: Buy Rating Supported by Promising OV329 Drug and Strategic Pipeline Development
2M ago
Ovid Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
PremiumRatingsOvid Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
3M ago
Ovid Therapeutics reports Q1 EPS (14c), consensus (13c)
Premium
The Fly
Ovid Therapeutics reports Q1 EPS (14c), consensus (13c)
3M ago
Ovid Therapeutics sees cash runway into 2H26
Premium
The Fly
Ovid Therapeutics sees cash runway into 2H26
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100